Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits

The use of novel agents such as thalidomide, lenalidomide, and bortezomib has considerably improved the outcome of multiple myeloma patients. Besides greater biological activity, these drugs unfortunately have also been associated with greater toxicity. To evaluate the positive effect on the quality...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrucci, Maria Teresa, Finsinger, Paola, Chisini, Marta, Gentilini, Fabiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094627/
https://www.ncbi.nlm.nih.gov/pubmed/25045252
http://dx.doi.org/10.2147/PPA.S38142
_version_ 1782325868970901504
author Petrucci, Maria Teresa
Finsinger, Paola
Chisini, Marta
Gentilini, Fabiana
author_facet Petrucci, Maria Teresa
Finsinger, Paola
Chisini, Marta
Gentilini, Fabiana
author_sort Petrucci, Maria Teresa
collection PubMed
description The use of novel agents such as thalidomide, lenalidomide, and bortezomib has considerably improved the outcome of multiple myeloma patients. Besides greater biological activity, these drugs unfortunately have also been associated with greater toxicity. To evaluate the positive effect on the quality of life of patients, driven by both the tolerability and antimyeloma activity of bortezomib, we analyzed data that have been published concerning different strategies used to improve its tolerability as once weekly and/or subcutaneous administration.
format Online
Article
Text
id pubmed-4094627
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-40946272014-07-18 Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits Petrucci, Maria Teresa Finsinger, Paola Chisini, Marta Gentilini, Fabiana Patient Prefer Adherence Review The use of novel agents such as thalidomide, lenalidomide, and bortezomib has considerably improved the outcome of multiple myeloma patients. Besides greater biological activity, these drugs unfortunately have also been associated with greater toxicity. To evaluate the positive effect on the quality of life of patients, driven by both the tolerability and antimyeloma activity of bortezomib, we analyzed data that have been published concerning different strategies used to improve its tolerability as once weekly and/or subcutaneous administration. Dove Medical Press 2014-07-04 /pmc/articles/PMC4094627/ /pubmed/25045252 http://dx.doi.org/10.2147/PPA.S38142 Text en © 2014 Petrucci et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Petrucci, Maria Teresa
Finsinger, Paola
Chisini, Marta
Gentilini, Fabiana
Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
title Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
title_full Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
title_fullStr Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
title_full_unstemmed Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
title_short Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
title_sort subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094627/
https://www.ncbi.nlm.nih.gov/pubmed/25045252
http://dx.doi.org/10.2147/PPA.S38142
work_keys_str_mv AT petruccimariateresa subcutaneousbortezomibformultiplemyelomatreatmentpatientsbenefits
AT finsingerpaola subcutaneousbortezomibformultiplemyelomatreatmentpatientsbenefits
AT chisinimarta subcutaneousbortezomibformultiplemyelomatreatmentpatientsbenefits
AT gentilinifabiana subcutaneousbortezomibformultiplemyelomatreatmentpatientsbenefits

Ejemplares similares